Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Tyme Technologies Inc is a biotechnology business based in the US. Tyme Technologies shares (TYME) are listed on the NASDAQ and all prices are listed in US Dollars. Tyme Technologies employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$0.97|
|52-week range||$0.85 - $3.48|
|50-day moving average||$1.02|
|200-day moving average||$1.23|
|Wall St. target price||$9.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-22)||N/A|
|3 months (2021-07-26)||-29.42%|
|6 months (2021-04-26)||-39.88%|
|1 year (2020-10-23)||0.53%|
|2 years (2019-10-25)||-32.36%|
|3 years (2018-10-25)||2.18|
|5 years (2016-10-25)||3.69|
|Gross profit TTM||$0|
|Return on assets TTM||-25.67%|
|Return on equity TTM||-46.44%|
|Market capitalisation||$167.7 million|
TTM: trailing 12 months
There are currently 3.0 million Tyme Technologies shares held short by investors – that's known as Tyme Technologies's "short interest". This figure is 4% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Tyme Technologies shares can be evaluated.
Tyme Technologies's "short interest ratio" (SIR) is the quantity of Tyme Technologies shares currently shorted divided by the average quantity of Tyme Technologies shares traded daily (recently around 958086.90095847). Tyme Technologies's SIR currently stands at 3.13. In other words for every 100,000 Tyme Technologies shares traded daily on the market, roughly 3130 shares are currently held short.
However Tyme Technologies's short interest can also be evaluated against the total number of Tyme Technologies shares, or, against the total number of tradable Tyme Technologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tyme Technologies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Tyme Technologies shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Tyme Technologies shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tyme Technologies.
Find out more about how you can short Tyme Technologies stock.
We're not expecting Tyme Technologies to pay a dividend over the next 12 months.
Tyme Technologies's shares were split on a 21654:4997 basis on 25 September 2014. So if you had owned 4997 shares the day before before the split, the next day you'd have owned 21654 shares. This wouldn't directly have changed the overall worth of your Tyme Technologies shares – just the quantity. However, indirectly, the new 76.9% lower share price could have impacted the market appetite for Tyme Technologies shares which in turn could have impacted Tyme Technologies's share price.
Over the last 12 months, Tyme Technologies's shares have ranged in value from as little as $0.85 up to $3.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tyme Technologies's is 0.927. This would suggest that Tyme Technologies's shares are less volatile than average (for this exchange).
Tyme Technologies, Inc. , a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.